Health & Biotech
Actinogen Medical gets a further boost from supportive FDA advice, shares up 7-fold in 2021
Health & Biotech
Stock Insiders: SKN lands $20M equity facility deal, accelerates COVID-19 ‘Invisi Shield’ rollout
Health & Biotech
NeuroScientific Biopharmaceuticals now has a research partner for its Phase I EmtinB trial
Health & Biotech
Suda Pharma pops 44pc on cap raise; Acrux and other biotechs whet investor appetites
Health & Biotech
‘Massive’ opportunity in psychedelic-based therapy, expert says
Health & Biotech
Acrux shares gain after FDA approves its toenail fungus treatment
Health & Biotech
NeuroScientific Biopharmaceuticals recruits Paradigm’s Paul Rennie as non-executive chairman
Health & Biotech
Global pharma leader Vectura will help Incannex develop its concussion treatment drug
Health & Biotech
Dr Boreham’s Crucible: Time to make a song and dance about Actinogen (ASX:ACW)?
Health & Biotech
ScoPo’s Powerplays: ‘Prepare for a big jump in July’ as tax-loss selling in healthcare continues
Health & Biotech
Creso Pharma is Canada-bound after announcing a merger with Red Light Holland
Health & Biotech
Weed Week: Amazon all-in on marijuana; free joints for jabs and Creso Pharma dual-listed in US
Featured Health & Biotech Stocks
Health & Biotech
Healthcare stocks are as varied as the solutions they are working to solve. The sector covers biotech stocks developing breakthrough pharmaceutical drugs and vaccines to medtech companies launching the latest and greatest medical devices they hope will change the face of healthcare.
Even the ‘budding’ medical cannabis industry is in the mix as researchers explore new applications and treatments.
If you want to know what’s happening with emerging health stocks on the ASX, Stockhead has you covered, with daily stock news, expert insight and research. You can also recap broader industry trends and recent share price movements across the sector in our regular ‘Check Up’ feature.
Accurate, up-to-date news stories are important, especially in the health sector where progress is often slow and risk often high. That’s why we’re focused on helping small cap investors make sense of the medical jargon.